Search Results
Your search for The ASCO Post,The ASCO Post matches 17617 pages
Showing 15101 - 15150John H. Saiki, MD, SWOG Investigator, Dies at 77
John “Jack” Harris Saiki, MD, Professor Emeritus at the University of New Mexico Department of Medicine, Hematology/Oncology Division, lived the history of modern day oncology with a career spanning 44 years. In the early days of his career, with the support of a grant from the federally funded New ...
How Evolutionary Game Theory Is Offering Clues to Disrupt Cancer Cell Metabolism
Kenneth J. Pienta, MD, and his colleagues at Johns Hopkins Medicine in Baltimore are using the principles of evolutionary game theory to learn how cancer cells cooperate within a tumor to gather energy and metastasize. Game theory, the mathematic study of strategic decision-making that is commonly...
Residents Association Recognizes 57 Mentors and Teachers With 2014 Educator of the Year Award
The Association of Residents in Radiation Oncology (ARRO) has honored 57 educators with the 2014 Educator of the Year Award. The award, presented annually, recognizes outstanding teachers and mentors of radiation oncology residents. Each radiation oncology residency program may nominate one faculty ...
‘Everybody Has a Mutation or More’
While genome sequencing is not currently recommended or widely used because of its high cost and paucity of meaningful, actionable results, some patients wouldn’t want it even if it were free and useful, Theodora Ross, MD, PhD, Director of the Cancer Genetics Program at the University of Texas...
News of Mutations in PALB2 Gene Raising Risk of Breast Cancer Offers Opportunity to Explain Limits of Genetic Testing
The response among patients to news reports about mutations in a gene known as PALB2 raising the risk of breast cancer “has been predictable,” Theodora Ross, MD, PhD, wrote in The New York Times.1 As an example, Dr. Ross, Director of the Cancer Genetics Program at The University of Texas...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
ASTRO Honors Jasan Zimmerman With 2014 Survivor Circle Award
The American Society for Radiation Oncology (ASTRO) presented the 2014 Survivor Circle Award to San Francisco Bay Area resident and cancer survivor Jasan Zimmerman during ASTRO’s 56th Annual Meeting held recently in San Francisco. The Survivor Circle Award recognizes a cancer survivor who lives in...
Arizona Health Science Center Appoints Rick Kittles, PhD, Director of New Division of Population Genetics
Rick Kittles, PhD, a national leader on cancer health disparities and the role of genes and environment in disease, and a pioneer in DNA testing to trace the ancestry of African Americans, has been appointed Director of the new Division of Population Genetics, part of the new Center for Applied...
ASTRO Awards Seven Physicians a Total of $675,000 to Fund Radiation Oncology-Specific Studies
The American Society for Radiation Oncology (ASTRO) presented seven physicians a total of $675,000 in awards and grants to advance radiation oncology research. The awards will fund studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research, ...
I Work for You
The following essay by James O. Armitage, MD, is excerpted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was co-edited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and at thebigcasino.org. The ...
Cancer Frontier: Bringing the New Sciences to an Old School
Cancer seems to have an endless supply of people who want to write about it. Why not? It’s an intriguing subject of life and death and struggle and hope, one that touches virtually every person of a certain age. However, the bookshelves are filled with cancer survivorship books, so to stand out, an ...
2014 Oncology Meetings
SEPTEMBER Celebrating 100 Years of Retinoblastoma Center in New York: 1914-2014September 18-19 • New York, New York For more information: www.mskcc.org/events/cme Palliative Medicine and Supportive Oncology 2014 – The 17th International SymposiumSeptember 18-20 • Henderson, Nevada For more...
Potential of Liquid Biopsies in Detecting Cancer and Establishing Prognosis
Tests in development to detect circulating tumor cells that escape from solid tumors and travel through the blood, spreading cancer to new sites, may serve as an alternative to conventional tissue biopsy for early cancer diagnosis and gene-expression analysis over the next decade. According to...
FDA Grants Priority Review to Lanreotide Injection for Gastroenteropancreatic Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review to Ipsen’s supplemental New Drug Application (sNDA) for the somatostatin analog lanreotide (Somatuline Depot) 120 mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors. The FDA designates...
Delivering Cancer Care in Low-Income Countries
In eealthy industrialized nations like the United States, escalating costs of cancer care have put the term “cost-effective care” on the forefront of health-care policy discussions. However, the cost issues we wrestle with in our $3 trillion health-care system are vague abstractions for much of the ...
Drew Pinsky, MD, Elected to Prostate Cancer Foundation Board of Directors
The Prostate Cancer Foundation has announced that Drew Pinsky, MD, has been elected to the Foundation’s Board of Directors. Dr. Pinsky, a cancer survivor, is a Practicing Physician and a Member of the Staff of Huntington Memorial Hospital in Pasadena, California. He is also Assistant Clinical...
Gene Therapy Betters Chemotherapy Tolerance, Effectiveness in Small Glioblastoma Study
Using gene therapy and a combination of chemotherapy drugs, researchers at Fred Hutchinson Cancer Research Center have been able to enhance the tolerance and effectiveness of medications used in treating glioblastoma while also protecting healthy cells from their toxic effects. The report,...
Moffitt Appoints Louis B. Harrison, MD, New Chair, Radiation Oncology
Louis B. Harrison, MD, has joined Moffitt Cancer Center in Tampa as Chair of the Department of Radiation Oncology, and Senior Member. Moffitt’s Radiation Oncology program includes faculty of cancer specialists who provide comprehensive cancer care for tumors at all anatomical locations, as well as...
UNC Lineberger Secures Three Major NCI Grants to Advance the Nation’s Clinical Trials Program
At the national level, clinical trials are seeing a lot of change. In an effort to increase efficiency and keep up with national changes in the types of clinical trials offered to cancer patients, the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN) is undergoing a major...
Breast Cancer Screening Using Tomosynthesis in Combination With Digital Mammography
In a study reported in JAMA and reviewed in this issue of The ASCO Post, Friedewald and colleagues1 showed that the addition of tomosynthesis to digital mammography2 resulted in a decrease in the screening recall rate3 and an increase in the cancer detection rate.4,5 This retrospective analysis of...
National Cancer Institute Launches the National Clinical Trials Network to Expedite Scientific Advances
In March, the National Cancer Institute (NCI) transformed its Cooperative Group Program into the National Clinical Trials Network (NCTN). Spurred by recommendations in the Institute of Medicine (IOM) 2010 report, A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI...
NIH Launches Human Safety Study of Ebola Vaccine Candidate
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched initial human testing of an investigational vaccine to prevent Ebola virus disease, according to a news release issued by NIH. The early-stage trial has begun initial human...
Kenneth S. Ramos, MD, PhD, PharmB, Named New MD-PhD Head at University of Arizona College of Medicine, Tucson
Kenneth S. Ramos, MD, PhD, PharmB, has been named the new MD-PhD Program Director at the University of Arizona College of Medicine, Tucson. The Program was established in 1990 to provide dual training in medicine and research to students interested in careers as research-intensive physicians...
Timing and Meaning of Do-Not-Resuscitate Orders in the Palliative Care Setting
Although a do-not-resuscitate (DNR) order does not mean “do not treat,” that is how it is often interpreted, according to a study examining the level of care oncology inpatients at a tertiary care hospital received.1 The study found that the interpretation of DNR orders among oncology nurses and...
CDC’s Breast and Cervical Screening Program Benefits Millions of Underserved Women in the United States
More than 4.3 million women with limited access to health care received breast and cervical cancer screening and diagnostic services in the first 20 years of the Centers for Disease Control and Prevention (CDC) National Breast and Cervical Cancer Early Detection Program. From 1991 to 2011, 56,662...
Complications No Different Between Open and Robot-Assisted Radical Cystectomy When Open Urinary Diversion Performed
We read the letter to the editor in the July 24, 2014, issue of The New England Journal of Medicine entitled, “A Randomized Trial of Robot-Assisted Laparoscopic Radical Cystectomy,” with great interest.1 Provocative Results In the letter, reviewed in this issue of The ASCO Post, Bochner and...
City of Hope Investigator Receives Grant for Immunotherapy Research
The Damon Runyon Cancer Research Foundation has awarded a $450,000 grant to an investigator studying T cells at City of Hope in Duarte. Elizabeth Budde, MD, PhD, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, Duarte, received The Jake...
Rwanda Offers Women Free Cervical Cancer Screening, HPV Vaccination
Cervical cancer is one of the major killers among women in Rwanda, and with the support of Rwanda’s First Lady, Jeannette Kagame, the country is rolling out a free human papillomavirus (HPV) vaccination and cervical cancer screening program in collaboration with Marck, Qiagen (a Dutch...
NCCN Marks 20 Years of Evidence-Based Decision-Making in Small Cell Lung Cancer
The National Comprehensive Cancer Network (NCCN) recently announced publication of the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC). One of the eight original NCCN Guidelines, the NCCN Guidelines for SCLC was initially...
PALB2 Study: Researchers and Patients Must 'Pal' for Progress
The recent publication by Antoniou et al on risk of breast cancer in PALB2 carriers,1 reviewed in this issue of The ASCO Post (page 47), is a contribution to the interesting history of the PALB2 gene, and an important milestone in the expansion of hereditary cancer susceptibility testing in the...
Patient-Reported Outcomes in Hematology and Oncology Product Development
INSIDE THE BLACK BOX is an occasional column providing insight into the U.S. Food and Drug Administration (FDA) and its policies and procedures. In this installment, Virginia Kwitkowski, MS, RN, ACNP-BC, and Elektra Papadopoulos, MD, MPH, discuss FDA’s current approach to the review of study...
Researchers at University of Michigan Receive $2.3 Million Grant to Promote Safety, Reduce Exposure Risk, at Chemotherapy Infusion Sites
Researchers at the University of Michigan School of Nursing and Comprehensive Cancer Center have received a $2.3 million grant to study oncology nurses’ exposure to hazardous drugs, including identifying ways to reduce exposure. “There are significant acute and long-term side effects from hazardous ...
Fox Chase Cancer Center Announces New Staff
Fox Chase Cancer Center has announced the appointment of two staff to the Center’s Department of Radiation Oncology and Surgical Oncology, respectively. Mark A. Hallman, MD, PhD, joins the Department of Radiation Oncology having served there recently as the Department’s Chief Resident. Sanjay S....
2014 Lasker Award
The Albert and Mary Lasker Foundation has announced Mary-Claire King, PhD, of the University of Washington, Seattle, will receive the 2014 Lasker~Koshland Special Achievement Award for her contributions to medical science and human rights. Dr. King’s demonstration of the existence of familial...
Angiogenesis in Ovarian Cancer: Are We Missing the Clinical Target?
Production of vascular endothelial growth factor (VEGF) is increased during normal ovulation, and can account for much of the reversible toxicity associated with ovarian hyperstimulation.1,2 We also have compelling data from multiple clinical trials to validate the importance of tumor-associated...
Early Study Finds Olaparib Tablet Safe in Pretreated Ovarian Cancer Patients; More Effective in Those With BRCA Mutations
An oral tablet form of a poly-ADP ribose polymerase (PARP) inhibitor, olaparib, given in combination with chemotherapy, was safe in heavily pretreated patients with ovarian cancer, and patients with BRCA mutations may have a better response compared with those without a BRCA mutation, according to...
PSA—It Just Keeps Getting Better, So Why Should It Stand Alone?
The updated results of the European Randomised Study of Screening for Prostate Cancer (ERSPC)—reported in The Lancet by Fritz H. Schröder, MD, of Erasmus University Medical Center, and colleagues1 and reviewed in this issue of The ASCO Post—show a continued decline, as predicted,2 in the number...
FDA Grants Fast Tract Designation to Investigational Combination Therapy In Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme Therapeutics’ program investigating pegylated recombinant human hyaluronidase (PEGPH20) in combination with gemcitabine and albumin-bound paclitaxel (nab-paclitaxel [Abraxane]) for the treatment of patients...
Novel Immunotherapy for Ovarian Cancer Receives Fast Track Designation
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin for the treatment of women with ovarian cancer whose disease has progressed on or recurred after...
FDA Approves Pembrolizumab for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to the anti–PD-1 antibody pembrolizumab (Keytruda) for the treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs. Pembrolizumab is intended for use following treatment...
‘Paradigm-Shifting’ Results in Treatment of Hematologic Disorders
The three leukemia/lymphoma studies selected from the many 2014 ASCO Annual Meeting abstracts for presentation at the recent Best of ASCO meeting in Chicago “are really paradigm-shifting,” noted Lucy A. Godley, MD, PhD, of the University of Chicago. These studies, she said, “give great promise for...
In Managing Ovarian Cancer, Precision Medicine Is a Work in Progress
Precision medicine in the management of ovarian cancer “is a work in progress, to be sure,” Steven B. Newman, MD, noted in wrapping up the session on gynecologic cancer at the recent Best of ASCO meeting in Chicago. “A list of different histologic types of ovarian cancer and potential targets are...
Disparities Persist in Early-Stage Breast Cancer Treatment, MD Anderson Study Finds
Despite its acceptance as standard of care for early-stage breast cancer almost 25 years ago, barriers still exist that preclude patients from receiving breast-conserving therapy, with some patients still opting for a mastectomy, according to research from The University of Texas MD Anderson Cancer ...
9/11 and Cancer: What Do We Know?
On September 11, 2001, the devastating terrorist attack that destroyed the World Trade Center left in its wake a unique toxic site in both mass and quantity of hazardous materials. It took 9 months to remove approximately 2 million tons of wreckage from Ground Zero, during which thousands of...
Top 5 Advances in Modern Oncology
1. Chemotherapy Cures Advanced Hodgkin Lymphoma In the first chemotherapy breakthrough for advanced cancer in adults, a four-drug combination chemotherapy regimen, called MOPP (mustargen/oncovin/procarbazine/prednisone), induced long-term remissions in over half of patients with aggressive Hodgkin ...
ASCO 50th Anniversary Poll Names the Top 5 Advances From the Past 50 Years
ASCO has announced the “Top 5 Advances in 50 Years of Modern Oncology,” based on results of worldwide voting on CancerProgress.Net—ASCO’s interactive website documenting the history of progress against cancer. The “Top 5 in 50” results identify pivotal discoveries in chemotherapy, prevention,...
Troubled by Hypocrisy
I am troubled by hypocrisy. An article in the July 25th edition of The ASCO Post on “Stakeholders Are Uniting Around Value in Cancer Care” (July 25, 2014, page 1) tells us how we must “rein in” costs. The vast majority of the articles in this issue, however, trumpet the “new wonder drugs” that we...
Expert Consensus Recommends Echocardiograph as Cornerstone to Protecting Cancer Patients’ Heart Health
Patients with cancer and survivors of cancer are living longer than ever before as a result of significant advances made over the past decade. Importantly, however, cardiovascular complications of their cancer treatment may present a life-threatening issue after their cancer treatment has ended....
LIVESTRONG Narrows Finalists in ‘Big C’ Competition: Winner to Be Announced This Month
Newly launched in 2014 by LIVESTRONG, “The Big C” is a one-of-a-kind global competition to generate innovations that improve the daily quality of life for the 32.5 million people around the world living with cancer now. The competition was open to entrepreneurs, trailblazers, technology whizzes,...
Moderate Form of Male Pattern Baldness Associated With Increased Risk of Aggressive Prostate Cancer
Men with moderate pattern baldness on the front and the crown of the head at age 45 had a 40% increased risk, compared to men with no baldness at that age, of developing prostate cancer later in life, according to a study led by researchers from the National Cancer Institute (NCI) and published in...
